Greenway Greenhouse Cannabis Corporation (CSE: GWAY) announced Monday that it has entered the Shelter Market’s Value Ounce Program through a collaboration with Agro-Greens Natural Products Ltd., which operates as Shelter and Shelter Market.
Jamie D’Alimonte, CEO and co-chair of the Kingsville, Ontario-based company said that Greenway is “proud to contribute to Canada’s medical cannabis access and affordability.”
Value Ounce Program enables access to affordable medical cannabis through competitive pricing agreements between Shelter and their cultivators.
D’Alimonte stressed that cannabis helps nearly 300 000 Canadians to sustain their health and quality of life.
“Until medical cannabis is zero-rated or …
Source Here: benzinga.com
Celebrating the Life and Legacy of Peter Tosh
This article was originally published on The Bluntness and appears here with permission.
If you’ve never listened to the music of Peter Tosh, if you’ve never done the deep dive – you owe it to yourself to do that now.
Pull up a YouTube mix, hit shuffle on Spotify, read the man’s bio – you will immediately connect …
Original Source: benzinga.com
Can Genetic Tests Help Diagnose Cannabinoid Hyperemesis Syndrome?
This article was originally published on WeedMaps and appears here with permission.
As awareness of cannabinoid hyperemesis syndrome (CHS) expands, both among medical doctors and patients, we are collectively becoming more and more able to identify a condition that has been historically hard to diagnose. After all, it seems counterintuitive that cannabis can cause many of the symptoms it’s used to treat.
Researchers are taking the current understanding of this severe and often debilitating condition one step further by attempting to pinpoint genetic markers that could be used to more readily diagnose CHS. This could potentially prevent those who are vulnerable from developing it in the first place.
Below, find out how CHS relates to genetics and what is being done in the medical world to combat the onset of the cannabis-based condition.
What is cannabinoid hyperemesis syndrome?
Still not widely known or completely understood, cannabinoid hyperemesis syndrome is a condition that is characterized by a strong, and often enduring, sensitivity to THC — and possibly other cannabinoids. CHS causes ongoing abdominal pain, cramping, nausea, and vomiting when cannabis is consumed.
What causes CHS?
While our understanding of the condition is still developing, CHS seems to occur most often in folks who consume high-potency cannabis and cannabis products regularly for long periods of time. What is happening in the body is a long-term and intense stimulation of the endocannabinoid system (ECS), along with other receptors and systems outside the ECS.
While medical science is still working to uncover the more complex and nuanced factors contributing to CHS, according to Dr. Ethan Russo, a renowned pioneer in cannabis research, it might be fair to say that CHS isn’t a functional gastrointestinal disorder so much as a “manifestation of gene and environmental interaction in a rare genetic disease, unmasked by excessive THC exposure.”
What doesn’t cause CHS? Pesticides.
Dr. Russo thinks it’s important to dispel the myth that CHS is caused by the pesticides or neem oil used in plant cultivation. “That just doesn’t hold water as an explanation,” Dr. Russo said. “There are more pesticides in use now than when CHS was first discovered, and pesticide reactions are quite different to what we see with CHS. Additionally, it’s been shown that synthetic cannabinoids, which are quite potent, can induce CHS — and while they are not pure, they don’t have pesticides in them.”
The difficulty and high cost of diagnosing CHS
The primary symptoms of CHS — cyclic abdominal cramping, nausea, and vomiting — are not unique to this condition, making CHS hard to diagnose. Because of this, CHS is considered among doctors to be a “diagnosis of exclusion,” or a diagnosis that is made when all other probable causes are ruled out.
According to an estimate made in a 2019 study, it took the average ER a whopping $76,920.92 in related testing expenses to diagnose CHS, while a 2018 paper estimated the average patient cost of a
Original Article: benzinga.com
Cannabis Prosecutions in Ireland Fell by Nearly Half in 2021
This article was originally published on Cannabis & Tech Today and appears here with permission.
As cannabis legalization efforts continue to gain momentum on the European continent, smaller reforms are also taking hold.
Cannabis decriminalization is one such reform, and thankfully, more European nations are enacting cannabis decriminalization policies.
Decriminalization may not be as good as outright legalization, but it’s better than subjecting people to jail time.
Ireland is one country in Europe that has decriminalized cannabis in some instances. According to new data, it’s a policy that appears to be working.
Prosecutions Reduced Dramatically
Under current law, …
Banks3 months ago
New Amsterdam FC Issues Equity to Every Professional Player, Likely…
Banks3 months ago
Vista Lending Receives “Top Mortgage Company” Award and Its Loan…
Tech2 months ago
NAI Introduces New Steady Link™ Series-S GPS & Sync Cable…
Health Care2 months ago
Lifeist Wellness’ CannMart Labs Kicks Off Commercialization of House Brands
Health Care2 months ago
Marley One-Branded Functional Mushroom Products Now Sold on Amazon
Arts3 months ago
‘Still a Bit Messy’ Angel Adoree Admits Escape to the Chateau Wedding Plans Are on Hold
Health Care3 months ago
Christina Lake Cannabis: Shares up on Third-Quarter 495% Gross Revenue Growth QoQ
Tech3 months ago
Pebblebee Found LTE – the Next Generation GPS Dog Tracker Is Now…